<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, pathology, clinical features, and diagnosis of meningioma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, pathology, clinical features, and diagnosis of meningioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, pathology, clinical features, and diagnosis of meningioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Park, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Meningiomas are the most frequent primary brain tumors  (<a class="graphic graphic_table graphicRef81566" href="/z/d/graphic/81566.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef72275" href="/z/d/graphic/72275.html" rel="external">figure 1</a>). Although most meningiomas are benign, their location in the central nervous system (CNS) can cause serious morbidity or mortality.</p><p>The epidemiology, pathology, clinical presentation, and diagnosis of meningiomas will be reviewed here. Other topics on meningioma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of World Health Organization (WHO) grade 1 (benign) meningiomas (see  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of WHO grade 2 and 3 meningiomas (see  <a class="medical medical_review" href="/z/d/html/15692.html" rel="external">"Management of atypical and malignant (WHO grade 2 and 3) meningioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic therapy for recurrent meningioma (see  <a class="medical medical_review" href="/z/d/html/15693.html" rel="external">"Systemic treatment of recurrent meningioma"</a>)</p><p></p><p class="headingAnchor" id="H1844514771"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Meningiomas are the most common primary central nervous system (CNS) tumors and account for approximately one-third of all primary brain and spinal tumors [<a href="#rid1">1,2</a>].</p><p>According to the Central Brain Tumor Registry in the United States (CBTRUS), there were 145,916 new cases of meningioma diagnosed from 2011 to 2015 [<a href="#rid3">3</a>]. The estimated number of new cases per year in the United States is nearly 29,000. The incidence rate varies by race, with Black Americans having a 1.2-fold higher incidence than White Americans [<a href="#rid3">3</a>].</p><p>The incidence of meningioma increases progressively with age, with a median age at diagnosis of 65 years. Meningiomas are rare in children [<a href="#rid4">4</a>], except in those with hereditary syndromes such as <em>NF2</em>-related schwannomatosis or antecedent therapeutic radiation therapy [<a href="#rid5">5,6</a>]. (See <a class="local">'Risk factors'</a> below.)</p><p>Meningiomas are more common in women, with a female-to-male ratio of approximately two or three to one [<a href="#rid7">7,8</a>]. For spinal meningiomas, which comprise approximately 10 percent of all meningiomas, the female-to-male ratio is even higher, approximately nine to one. This female predominance is highest in middle-aged adults (35 to 54 years) and less pronounced or absent in those with atypical or anaplastic meningiomas, children, and those with radiation-induced meningiomas.</p><p>Population-based studies estimate that 80 to 85 percent of meningiomas are World Health Organization (WHO) grade 1, approximately 15 to 18 percent are grade 2, and 1 to 3 percent are grade 3 [<a href="#rid3">3</a>]. Hospital-based studies, particularly from tertiary care centers, have reported a higher proportion of grade 2 and 3 tumors [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H2026977135"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>A number of factors have been studied for a possible relationship to the development of meningiomas and other brain tumors. The factors most intensively investigated as having a potential etiologic role in meningioma are discussed here. Factors associated with other types of brain tumors are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">"Risk factors for brain tumors"</a>.)</p><p class="headingAnchor" id="H364101638"><span class="h2">Ionizing radiation</span><span class="headingEndMark"> — </span>Exposure to ionizing radiation is the most important acquired risk factor for meningioma [<a href="#rid11">11,12</a>]. Radiation-induced meningiomas have a higher incidence of multiplicity and atypia compared with sporadic meningiomas. An increased risk of meningioma following a lengthy latency period has been established in a variety of situations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy for malignancy</strong> – Therapeutic use of radiation can result in exposure of the central nervous system (CNS) either as a direct consequence of treatment or by incidental exposure. Clinical situations in which this is particularly important include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Radiation therapy for primary malignancies of the CNS</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Radiation therapy for tumors in the head and neck region</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylactic craniospinal irradiation to prevent CNS relapse as a component of treatment for acute leukemia or other malignancy</p><p></p><p class="bulletIndent1">Although the absolute risk associated with radiation therapy is not known, the latency period is more than 20 years in many cases. Long-term follow-up of epidemiologic studies has observed that the incidence continues to rise even after several decades, and that risk may be highest among patients treated at a young age [<a href="#rid6">6,13-17</a>]. In a cohort of over 4000 childhood cancer survivors exposed to cranial radiation, the cumulative risk of meningioma was 5.6 percent by age 40 years [<a href="#rid15">15</a>]. Cumulative incidence was highest among patients younger than five years at initial cancer diagnosis (10 percent); additional risk factors included female sex and increasing dose of radiation. A smaller study found a 12 percent cumulative incidence of meningioma by 40 years after exposure to cranial radiation in childhood [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidental radiation exposure</strong> – An association between radiation and the subsequent development of meningioma has been observed in a number of other clinical settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tinea capitis – Until the 1950s, low doses of irradiation were used to treat tinea capitis. An analysis of over 11,000 children treated for tinea capitis found a sevenfold increase in the incidence of meningioma, with a mean latency of 36 years [<a href="#rid11">11,18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dental radiographs – Several studies have reported an increased risk of meningioma associated with frequent dental radiographs [<a href="#rid19">19-24</a>]. Across multiple studies, the reported risk has been highest for multiple radiograph examinations and childhood exposure, primarily in an era when the dose of dental radiographs was higher than with current technology [<a href="#rid19">19,22,23,25</a>]. Importantly, recall bias can influence associations found in case-control studies such as these, and validation of dental records was not performed in most of these studies [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic head computed tomography (CT) – Childhood exposure to diagnostic head CTs may also be associated with an increased risk of brain tumors, including meningiomas [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging", section on 'Children and adolescents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atomic bomb exposure – An increased incidence of meningiomas has been observed in survivors of the atomic explosions in Japan [<a href="#rid29">29,30</a>]. The increased incidence of meningioma was more pronounced in those who received higher radiation doses and those who were younger at the time of exposure [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H1048806015"><span class="h2">Genetic predisposition</span><span class="headingEndMark"> — </span>A genetic predisposition to meningioma is best characterized in patients with <em>NF2</em>-related schwannomatosis (NF2) and other forms of schwannomatosis. Patients with multiple endocrine neoplasia type 1 (MEN1) also have an increased risk of meningioma, although at lower rates compared with neurofibromatosis [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Other tumors'</a>.)</p><p class="headingAnchor" id="H4082774615"><span class="h3"><i>NF2</i>-related schwannomatosis</span><span class="headingEndMark"> — </span><em>NF2</em>-related schwannomatosis (NF2) is an autosomal dominant disorder predisposing to multiple tumors of the nervous system. This disorder is caused by mutations in the NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor (<em>NF2</em>) gene, a tumor suppressor gene on chromosome 22. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Molecular pathogenesis'</a>.)</p><p>Approximately one-half of individuals with NF2 have meningiomas, and multiple meningiomas are often present [<a href="#rid33">33</a>]. Most meningiomas are intracranial, although intradural, extramedullary spinal meningiomas are also seen. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Meningiomas'</a>.)</p><p>The incidence increases with age, and lifetime risk of developing a meningioma may be as high as 75 percent [<a href="#rid34">34</a>]. Patients with NF2 tend to develop meningiomas at an earlier age than those with sporadic meningiomas. The meningiomas seen in patients with NF2 are more frequently atypical or anaplastic compared with sporadic tumors [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H4220608616"><span class="h3">Other schwannomatoses</span><span class="headingEndMark"> — </span>Meningiomas are recognized as part of the phenotype of other forms of schwannomatosis in some patients. Patients with non-<em>NF2</em>-related schwannomatosis have multiple schwannomas in the absence of bilateral vestibular schwannomas; germline mutations in the tumor suppressor gene <em>SMARCB1</em> are present in up to 50 percent of familial cases and a small proportion of sporadic cases. (See  <a class="medical medical_review" href="/z/d/html/16350.html" rel="external">"Schwannomatoses related to genetic variants other than <i>NF2</i>", section on 'Other tumors'</a>.)</p><p class="headingAnchor" id="H3598346857"><span class="h2">Hormonal factors</span><span class="headingEndMark"> — </span>Hormonal factors may have a role in the development of meningioma, as suggested by several lines of evidence [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of meningioma is higher in postpubertal women compared with men</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The female-to-male ratio is highest during the peak reproductive years and decreases in older adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progesterone and androgen receptors are present in approximately two-thirds of patients, while estrogen receptors have been identified in approximately 10 percent of cases [<a href="#rid37">37-39</a>]</p><p></p><p class="headingAnchor" id="H1939784858"><span class="h3">Low-dose estrogens and progestins</span><span class="headingEndMark"> — </span>Multiple observational studies have explored a possible relationship between low-dose estrogen and progestin exposure (eg, menopausal hormone therapy or oral contraceptive use) and the risk of meningioma, with mixed results [<a href="#rid1">1,40-47</a>]. A meta-analysis of six prospective case-control studies that included over 1600 meningioma cases found that ever-use of hormone therapy was associated with a small but statistically significant increase in the risk of meningioma (relative risk [RR] 1.35, 95% CI 1.2-1.5) [<a href="#rid46">46</a>]. In studies that distinguished between estrogen-only versus combined estrogen-progestin hormone therapy, estrogen, but not combined therapy, was associated with increased risk (RR 1.31). This is equivalent to an approximate absolute excess risk of 2 per 10,000 users over five years.</p><p>Some, but not all, studies have also suggested a protective effect of smoking and an increased risk with higher body mass index (BMI), both of which could potentially be mediated through their effects on endogenous estrogen levels [<a href="#rid40">40,43-45,47</a>].</p><p>Inhibition of estrogen or progesterone receptors has not been shown to alter the natural history of recurrent meningiomas, however. (See  <a class="medical medical_review" href="/z/d/html/15693.html" rel="external">"Systemic treatment of recurrent meningioma", section on 'Hormonal therapy'</a>.)</p><p class="headingAnchor" id="H4130184173"><span class="h3">High-dose cyproterone</span><span class="headingEndMark"> — </span>Cyproterone, an anti-androgen and progestin, is associated with a small increase in the risk of meningioma with increasing cumulative doses (eg, ≥25 mg per day over several years). It is contraindicated in people with a history of meningioma and should be discontinued if meningioma is diagnosed [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma", section on 'Patients with hormone exposure'</a>.)</p><p>Cyproterone is not available in the United States but is used in Europe and elsewhere at high doses (eg, ≥25 mg per day) for conditions that include advanced prostate cancer, severe hypersexuality in males, hirsutism, and androgen suppression in transgender females. Based on a European Medicines Agency (EMA) safety committee review, the occurrence of both single and multiple meningiomas has been reported in association with cyproterone, primarily at doses of 25 mg/day and above [<a href="#rid49">49</a>]. The absolute risk is estimated at between 1 and 10 per 10,000 people, depending on dose and duration of cyproterone. In a case-control study of &gt;1000 resected cyproterone-associated meningiomas in France, the median age at presentation was lower compared with nonexposed resected meningioma cases (47 versus 61 years), and there was a predilection for middle skull base location (39 versus 23 percent) [<a href="#rid50">50</a>]. In a separate French study that included 210 patients exposed to cyproterone or one of two other progestins who underwent MRI screening, the rate of meningioma detection was 7 percent; seven of these patients (47 percent) had multiple meningiomas [<a href="#rid51">51</a>]. The most common tumor locations were convexity (62 percent), middle skull base (21 percent), and anterior skull base (16 percent).</p><p>Available data have <strong>not</strong> shown a risk of meningioma with lower doses of cyproterone (1 to 2 mg alone or in combination with ethinylestradiol or estradiol valerate) used for acne, hirsutism, contraception, or menopausal hormone therapy. As a precaution, the EMA recommends avoiding cyproterone in people with a meningioma, even at these low doses [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2144618143"><span class="h2">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> – A moderately increased risk of meningioma has been reported in females with breast cancer, and, conversely, an increase in the incidence of breast cancer has been observed in females with a history of meningioma [<a href="#rid1">1,52,53</a>]. The magnitude of risk is not well established. A meta-analysis of 13 observational studies estimated a nearly 10-fold increase in the prevalence of breast cancer in females with meningioma compared with prevalence in the general population (odds ratio 9.87, 95% CI 7.31-13.32), although heterogeneity among studies was high and possible publication bias was identified [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Whether the association is due to shared hormonal risk factors, other risk factors causing both diseases, or an underlying genetic predisposition is unclear [<a href="#rid1">1</a>]. Given shared risks, clinicians should emphasize the importance of breast cancer screening in females with meningioma. (See  <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – A positive association between BMI and meningioma has been reported in several large observational studies, with odds ratios ranging from 1.4 to 2.1 [<a href="#rid40">40,43,47,54-58</a>]. This relationship might be related to endogenous hormonal factors, since obesity is associated with higher levels of estrogens and other growth factors.</p><p></p><p class="bulletIndent1">High BMI is an established risk factor for a variety of other neoplasms, including esophageal adenocarcinoma, endometrial cancer, colon cancer, and breast cancer [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">"Epidemiology and pathobiology of esophageal cancer", section on 'Obesity and metabolic syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Obesity'</a> and  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women", section on 'Weight and body fat in postmenopausal women'</a> and  <a class="medical medical_review" href="/z/d/html/2606.html" rel="external">"Epidemiology and risk factors for colorectal cancer", section on 'Obesity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Head trauma</strong> – Several studies have analyzed the role of head trauma as an etiologic factor for brain tumors, with conflicting results [<a href="#rid25">25,60-62</a>]. Improved recall of a history of head trauma in patients with meningioma may have contributed to bias in some of these studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell phones</strong> – Others have looked at a possible link between cell phone usage and the subsequent development of brain tumors. At present, there is no conclusive evidence supporting a causal relationship. However, the prolonged latency period seen with ionizing radiation suggests that longer follow-up is required [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">"Risk factors for brain tumors", section on 'Cellular phones and radiofrequency fields'</a>.)</p><p></p><p class="headingAnchor" id="H21293438"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H2247447367"><span class="h2">WHO classification</span><span class="headingEndMark"> — </span>Meningiomas are classified according to the World Health Organization (WHO) schema, which is based upon morphologic criteria [<a href="#rid63">63-66</a>]. The WHO classification system recognizes three grades, which can be assigned to 15 morphologic subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO grade 1</strong> – Benign meningiomas (WHO grade 1)  (<a class="graphic graphic_picture graphicRef60534" href="/z/d/graphic/60534.html" rel="external">picture 1</a>) span 13 subtypes. WHO grade 1 meningiomas do not meet any of the criteria for a higher-grade lesion based upon morphologic and molecular criteria. The treatment approach is the same for all of the subtypes of benign meningiomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO grade 2</strong> – WHO grade 2 meningiomas include specific morphologic subtypes (clear cell and chordoid meningiomas), tumors with increased mitotic activity (4 to 19 mitoses per 10 high-powered fields) or brain invasion, and tumors with three or more of the following features: increased cellularity, small cells with a high nuclear-to-cytoplasmic ratio, prominent nucleoli, uninterrupted patternless or sheet-like growth, and foci of spontaneous or geographic necrosis  (<a class="graphic graphic_picture graphicRef60534" href="/z/d/graphic/60534.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO grade 3</strong> – WHO grade 3 (malignant) meningiomas have ≥20 mitoses per 10 high-powered fields; malignant characteristics resembling carcinoma, sarcoma, or melanoma; or a high-risk molecular feature (telomerase reverse transcriptase [<em>TERT</em>] promoter mutation or homozygous cyclin-dependent kinase inhibitor 2A/B [<em>CDKN2A/B</em>] deletion)  (<a class="graphic graphic_picture graphicRef60534" href="/z/d/graphic/60534.html" rel="external">picture 1</a>). (See <a class="local">'Molecular risk stratification'</a> below.)</p><p></p><p>The WHO grading system correlates with outcome and thus has a major impact on treatment planning. Patients with WHO grade 2 or grade 3 meningiomas are significantly more likely to have invasive disease, a local recurrence following the initial treatment, and, ultimately, a shorter overall survival compared with patients with a WHO grade 1 meningioma.</p><p class="bulletIndent1"><span class="glyph">●</span>Overall reported rates of recurrence for patients with grade 1, 2, and 3 meningiomas are 7 to 25, 30 to 50, and 50 to 94 percent, respectively, in various series [<a href="#rid67">67-71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although WHO grade 3 meningiomas are considered malignant, distant metastasis is rare and the primary issue is local recurrence, which necessitates additional treatment beyond surgery and ultimately can cause death [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/15692.html" rel="external">"Management of atypical and malignant (WHO grade 2 and 3) meningioma"</a>.)</p><p></p><p>Among grade 1 tumors, the presence of atypical features may also have prognostic importance, although data are more limited. In a study of 147 patients who underwent resection of a grade 1 meningioma, the five-year recurrence rate was significantly higher for tumors with one or two atypical features compared with tumors with no atypical features (31 versus 14 percent), independent of extent of resection [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H2789618881"><span class="h2">Molecular risk stratification</span><span class="headingEndMark"> — </span>A growing number of individual molecular genetic alterations have been identified that are associated with more aggressive biology and worse outcomes, including mutations in the <em>TERT</em> promoter region, <em>CDKN2A/B</em> deletion, and loss of trimethylation of lysine 27 of histone 3 (H3K27me3) [<a href="#rid74">74-77</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TERT</em></strong><strong> alterations</strong> – <em>TERT</em> gene alterations in particular have been associated with an aggressive clinical course. In a multicenter retrospective study of 677 patients with meningioma, the prevalence of <em>TERT </em>gene alterations was 5, 8, and 15 percent for WHO grade 1, 2, and 3 tumors, respectively [<a href="#rid78">78</a>]. Median recurrence-free and overall survival were 14 months and 4.8 years for <em>TERT</em>-mutated tumors, compared with 8.4 and 13.3 years for <em>TERT</em>-wildtype tumors. While this may be partially explained by the higher relative incidence of WHO grade 3 tumors in the <em>TERT</em>-mutated group, the adverse effect on survival appeared to be independent of WHO grade in a multivariable analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>CDKN2A/B</em></strong><strong> deletion</strong> – In a study of 528 meningiomas, homozygous deletion of <em>CDKN2A/B</em> was identified exclusively in grade 2 (27 percent) and grade 3 tumors (73 percent) [<a href="#rid79">79</a>]. The median time to progression after surgery was substantially shorter in tumors carrying <em>CDKN2A/B</em> deletion (8 versus 101 months). Co-occurring <em>TERT </em>promoter mutations were present in three of six <em>CDKN2A/B</em>-deleted tumors that were tested for both alterations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>H3K27me3 loss</strong> – Loss of immunohistochemical staining for H3K27me3 is associated with increased risk for recurrence, especially in WHO grade 2 tumors [<a href="#rid80">80-82</a>]. In a large retrospective cohort of over 1100 meningiomas, H3K27me3 loss was observed in 3.1 percent of grade 1 tumors, 10.4 percent of grade 2 tumors, and 17.7 percent of grade 3 tumors [<a href="#rid80">80</a>]. On multivariate analysis, H3K27me3 loss was predictive of decreased recurrence-free survival (risk ratio [RR] 1.80), independent of sex, extent of resection, tumor grade, and proliferation index.</p><p></p><p>Classification of meningiomas into molecular groups by DNA and RNA profiling as well as the integration of molecular and morphologic features may also improve upon the prediction of biologic behavior and prognosis [<a href="#rid83">83-86</a>]. A three-tiered integrated grading scheme (Integrated Grades 1, 2, and 3) based on mitotic count, chromosomal copy-number data, and <em>CDKN2A </em>deletion status has been proposed, which more accurately predicts risk of recurrence than the WHO grading system [<a href="#rid87">87</a>]. Further validation is necessary, however, before this scheme can be used to guide treatment decisions.</p><p class="headingAnchor" id="H3059649254"><span class="h2">Molecular pathogenesis</span><span class="headingEndMark"> — </span>The best-characterized genetic alteration is loss of chromosome 22, which in many cases is associated with mutations in the <em>NF2</em> gene located on the long arm of chromosome 22. (See <a class="local">'NF2-related schwannomatosis'</a> above.)</p><p><em>NF2</em> mutations are also present in approximately one-half of sporadic meningiomas, more commonly in those with transitional or fibroblastic histologic subtypes and in higher-grade tumors [<a href="#rid88">88</a>].</p><p>Genomic sequencing efforts have identified several oncogenic mutations in a small subset of non-<em>NF2</em> mutant meningiomas that have potential therapeutic implications. In two separate studies, mutations in Smoothened (<em>SMO</em>), an activator of the Hedgehog pathway that is mutated in many basal cell carcinomas, were found in approximately 5 percent of tumors, and mutations in v-akt murine thymoma viral oncogene homolog 1 (<em>AKT1</em>), an activator of the phosphatidylinositol 3-kinase (PI3K) pathway, were found in up to 13 percent of tumors [<a href="#rid89">89,90</a>]. Mutations in <em>TRAF7</em>, a proapoptotic ubiquitin ligase, were identified in approximately one-quarter of tumors in one study [<a href="#rid90">90</a>]. The role of these mutations in the pathogenesis of meningioma, however, is unclear. Another study found oncogenic mutations in <em>PI3KA</em> in approximately 7 percent of meningiomas [<a href="#rid91">91</a>].</p><p>Many of these mutations appear to be most prevalent in anterior skull base tumors. In a series of 62 anterior skull base meningiomas, <em>SMO</em> mutations were present in 7 tumors (11 percent), all but one of which were in the olfactory groove, and <em>AKT1</em> mutations were present in 12 tumors (19 percent) [<a href="#rid92">92</a>]. Other studies suggest that <em>PI3KA</em> mutations also occur primarily in skull base tumors and might be overrepresented in progestin-exposed tumors [<a href="#rid91">91,93</a>].</p><p>Activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway also appears to be a common alteration in meningioma that has potential therapeutic implications [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Meningiomas can arise anywhere from the dura, most commonly within the skull and at sites of dural reflection (falx cerebri, tentorium cerebelli, venous sinuses) [<a href="#rid95">95</a>]. Other less common sites include the optic nerve sheath and choroid plexus; approximately 10 percent arise in the spine. Very rarely, meningiomas can arise at extradural sites [<a href="#rid96">96</a>].</p><p>Symptoms from a meningioma are determined by the location of the mass and by the time course over which the tumor develops. Meningiomas are frequently extremely slow growing and often are asymptomatic. (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Asymptomatic tumors</span><span class="headingEndMark"> — </span>Many meningiomas are asymptomatic or minimally symptomatic, and are discovered incidentally on a neuroimaging study or at autopsy [<a href="#rid97">97-101</a>]. Follow-up studies on patients with asymptomatic meningiomas suggest that most such tumors either remain the same size or grow slowly over prolonged periods [<a href="#rid102">102,103</a>].</p><p>In a systematic review and meta-analysis of incidental findings on brain magnetic resonance imaging (MRI) in nearly 20,000 children and adults, meningioma was the most common incidental tumor, identified on 0.29 percent of MRIs [<a href="#rid104">104</a>]. The prevalence of incidental findings, including meningioma, increases with age. In population-based studies of brain MRI in older adult volunteers (mean age 65 to 70 years), meningiomas are identified in approximately 2.5 percent of participants [<a href="#rid105">105,106</a>]. The most common locations are convexity (62 percent) and falx cerebri (15 percent) [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures are present preoperatively in approximately 30 percent of patients who are diagnosed with an intracranial meningioma [<a href="#rid107">107</a>]. The risk of seizure is higher in association with non-skull base location (eg, convexity and parasagittal/falcine tumors) and tumors associated with peritumoral edema.</p><p class="headingAnchor" id="H15"><span class="h2">Focal findings</span><span class="headingEndMark"> — </span>Characteristic focal deficits are caused by tumors in specific locations. Examples of such lesions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Visual changes – Visual changes, which are often unrecognized, are common in meningiomas involving the optic pathways.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Visual field defects may be caused by parasellar meningiomas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Optic atrophy in one eye and papilledema in the other, the so-called Foster-Kennedy syndrome, can be produced by parasellar or subfrontal meningiomas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive unilateral visual loss, which may be mistaken for optic neuritis, can be caused by optic nerve sheath meningiomas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild weakness of extraocular movements has been associated with cavernous sinus meningiomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of hearing or smell – A cerebellopontine angle meningioma can produce sensorineural hearing loss. Olfactory groove or sphenoid ridge meningiomas can cause anosmia due to compression of the olfactory tract.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mental status changes – Mental status changes with apathy and inattention may result from surprisingly large subfrontal or sphenoid ridge meningiomas. Similar or even larger-sized tentorial notch and intraventricular meningiomas are at times asymptomatic and diagnosed incidentally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extremity weakness – Meningiomas at different sites can produce characteristic patterns of extremity weakness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A parasagittal meningioma growing on the falx and compressing the motor strip can lead to bilateral leg weakness in the absence of a spinal cord lesion</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Foramen magnum meningiomas may produce a subtly progressive sequence of ipsilateral arm, then leg weakness, which is followed by contralateral leg and arm weakness that may be misdiagnosed as multiple sclerosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spinal meningiomas frequently present with progressive leg weakness and numbness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive hydrocephalus – Large tumors in the posterior cranial fossa can cause obstructive hydrocephalus, and present with papilledema and classic early morning headache.</p><p></p><p class="headingAnchor" id="H1094512137"><span class="h1">NEUROIMAGING</span><span class="headingEndMark"> — </span>Meningiomas have a very characteristic appearance on both MRI and CT  (<a class="graphic graphic_table graphicRef109029" href="/z/d/graphic/109029.html" rel="external">table 2</a>).</p><p>On MRI, a typical meningioma is an extra-axial, dural-based mass that is isointense or hypointense to gray matter on T1 and isointense or hyperintense on proton density and T2-weighted images. There is usually strong, homogeneous contrast enhancement after gadolinium administration  (<a class="graphic graphic_diagnosticimage graphicRef59777" href="/z/d/graphic/59777.html" rel="external">image 1</a>). Most meningiomas show a characteristic marginal dural thickening that tapers peripherally (the "tail" sign)  (<a class="graphic graphic_diagnosticimage graphicRef65731" href="/z/d/graphic/65731.html" rel="external">image 2</a>).</p><p>On CT, the typical meningioma is a well-defined extra-axial mass that displaces the normal brain. They are smooth in contour, adjacent to dural structures, and sometimes calcified or multilobulated. Isodensity with normal surrounding brain may make diagnosis difficult on a noncontrasted scan, but intravenous contrast administration results in uniformly bright enhancement. Secondary involvement of adjacent bone (reactive sclerosis, invasion, erosion) is uncommon with convexity meningiomas, but occurs in up to one-half of skull base tumors [<a href="#rid108">108</a>].</p><p>Differentiating an atypical or malignant meningioma from a benign meningioma purely on the basis of neuroimaging is difficult. Features on MRI that may suggest the presence of a high-grade meningioma rather than a benign meningioma include the following [<a href="#rid72">72,109-112</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intratumoral cystic change</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperostosis of the adjacent skull and/or bone destruction</p><p class="bulletIndent1"><span class="glyph">●</span>Extension of tumor through the skull base</p><p class="bulletIndent1"><span class="glyph">●</span>Peritumoral brain edema</p><p class="bulletIndent1"><span class="glyph">●</span>Low apparent diffusion coefficient (ADC) values</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated cerebral blood volume</p><p></p><p>However, none of these neuroimaging findings are sufficiently specific to be clinically useful. Furthermore, the initial therapeutic approach for most meningiomas is surgical resection if feasible, depending upon the size and location of the lesion, as well as the patient's overall condition and symptoms. (See  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma"</a>.)</p><p>18-F Fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning has shown more intense uptake associated with higher-grade meningiomas in some, but not all, studies and is of limited diagnostic value [<a href="#rid113">113</a>]. Novel PET tracers, including specific somatostatin receptor ligands, hold more promise but are not yet widely available for clinical use [<a href="#rid114">114,115</a>].</p><p>Prior to the development of MRI and CT, angiography was used to suggest the diagnosis of meningioma by demonstrating arterial supply from meningeal vessels and the delayed vascular blush that is characteristic of these lesions. The use of angiography now is limited to tumor embolization as a component of therapy. (See  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma", section on 'Extent of resection'</a>.)</p><p class="headingAnchor" id="H2499296516"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>While meningioma is by far the most common cause of a discrete, dural-based enhancing mass lesion, many other disease processes can involve the dura or subdural space, resulting in an appearance on MRI or CT that may suggest meningioma. These include lymphoma, plasmacytoma, metastatic carcinoma, melanocytic neoplasms, solitary fibrous tumor, gliosarcoma, inflammatory lesions such as sarcoidosis and granulomatosis with polyangiitis, and infections such as tuberculosis [<a href="#rid95">95,114,116-118</a>].</p><p>In general, MRI, CT, and positron emission tomography (PET) studies cannot reliably distinguish these entities from meningioma. The presence of atypical imaging features, such as large or disproportionate amount of associated edema, extensive bone involvement, or brain or leptomeningeal invasion, may be a clue to an alternative etiology or to a higher-grade meningioma, along with clinical features of systemic disease. These and other clinical clues to rare alternative diagnoses are reviewed in the table  (<a class="graphic graphic_table graphicRef109028" href="/z/d/graphic/109028.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H22"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>A definitive diagnosis of meningioma and classification as benign, atypical, or malignant (World Health Organization [WHO] grades 1, 2, and 3, respectively) requires histologic confirmation. However, imaging studies often provide a tentative diagnosis and may be sufficient for empiric treatment when obtaining tissue for pathologic confirmation entails too high a risk of causing further neurologic deficits.</p><p>While the differential diagnosis of meningioma includes a wide range of neoplastic and non-neoplastic entities, these are rare and almost always diagnosed after tissue is obtained, due to their clinical and radiographic similarity to meningiomas. The utility of an extensive preoperative evaluation is uncertain.</p><p class="headingAnchor" id="H2712535111"><span class="h2">History</span><span class="headingEndMark"> — </span>The history in patients with a suspected meningioma should include an assessment of risk factors, especially a history of prior therapeutic radiation. Radiation-induced meningiomas have a higher likelihood of being high grade and of being multiple and recurrent. (See <a class="local">'Ionizing radiation'</a> above and  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma", section on 'Radiation-induced meningiomas'</a>.)</p><p>The history should also probe for conditions that may cause dural-based pathology mimicking meningioma, including hematologic and nonhematologic malignancy, sarcoidosis, and tuberculosis  (<a class="graphic graphic_table graphicRef109028" href="/z/d/graphic/109028.html" rel="external">table 3</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p>Genetic syndromes predisposing to meningioma, such as <em>NF2</em>-related schwannomatosis (NF2) and other forms of schwannomatosis, may be apparent by personal and family history by the time a meningioma is identified. Lack of a family history does not rule these syndromes out, however, as de novo mutations frequently occur. (See <a class="local">'Genetic predisposition'</a> above.)</p><p class="headingAnchor" id="H1707060264"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Most patients with meningioma have a normal physical examination. Occasionally, convexity tumors associated with prominent hyperostosis or direct bony extension may produce a palpable bulge on the skull.</p><p>Physical stigmata of NF2 or schwannomatosis may include hearing loss (for NF2) and multiple palpable schwannomas. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/16350.html" rel="external">"Schwannomatoses related to genetic variants other than <i>NF2</i>", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H3765161906"><span class="h2">Laboratories</span><span class="headingEndMark"> — </span>It seems reasonable to obtain a comprehensive metabolic panel and complete blood count, as findings such as hypercalcemia or anemia might prompt additional testing for multiple myeloma or systemic malignancy. We do not routinely obtain serum protein electrophoresis (SPEP), urinalysis, angiotensin converting enzyme (ACE) level, or tuberculosis screening in otherwise healthy adults. More extensive evaluation should be considered in immunocompromised hosts and in patients with atypical imaging features.</p><p>Cerebrospinal fluid analysis does not play a role in the diagnostic evaluation of meningioma but may be indicated if there are atypical imaging features, such as leptomeningeal enhancement, suggesting involvement of the subarachnoid space.</p><p class="headingAnchor" id="H1012883900"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>MRI with contrast provides the most complete assessment of suspected meningiomas. Dedicated views through the involved region (eg, skull base protocol, orbital sequences) may be needed to adequately image small tumors in certain locations [<a href="#rid119">119</a>]. CT may also be obtained to provide better definition of bony anatomy and the degree of calcification associated with the lesion. (See <a class="local">'Neuroimaging'</a> above.)</p><p>We do not routinely obtain spinal imaging in patients with a suspected intracranial meningioma, but we do advise obtaining a brain MRI in patients with a suspected spinal meningioma to look for intracranial masses that may suggest either a tumor predisposition syndrome or an alternative diagnosis.</p><p>We obtain updated cancer staging (eg, chest, abdomen, and pelvis CT) in patients with known cancer but do not routinely obtain these tests in otherwise healthy adults who have undergone age-appropriate cancer screening. The presence of atypical neuroimaging findings, even in a patient without known cancer, may also indicate the need for a more extensive cancer staging.</p><p class="headingAnchor" id="H444766081"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Meningiomas account for approximately one-third of primary central nervous system (CNS) tumors, occurring primarily in older individuals with a female predominance  (<a class="graphic graphic_table graphicRef81566" href="/z/d/graphic/81566.html" rel="external">table 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The etiology of meningioma is not known in most cases. However, there is a clear association with antecedent radiation exposure, which is associated with a latency period that may exceed 30 years. Meningiomas are a frequent manifestation of <em>NF2</em>-related schwannomatosis, and somatic mutations in the <em>NF2</em> gene may also contribute to the development of sporadic meningiomas. (See <a class="local">'Risk factors'</a> above and <a class="local">'Molecular pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Meningiomas are classified according to the World Health Organization (WHO) grading system. WHO grade 1 lesions are benign and generally have a favorable prognosis, while atypical (grade 2) and malignant (grade 3) meningiomas are substantially more likely to recur. (See <a class="local">'WHO classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location</strong> – Meningiomas can arise anywhere from the dura, most commonly within the skull. Approximately 10 percent arise in the spinal cord. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Many meningiomas are slow growing and discovered incidentally on a neuroimaging study. These may be asymptomatic or minimally symptomatic. Symptoms of large tumors can vary widely, depending upon by the location of the mass. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – On MRI, a typical meningioma is an extra-axial, dural-based mass that is isointense or hypointense to gray matter on T1, isointense or hyperintense on proton density and T2-weighted images, and associated with strong, homogeneous contrast enhancement after gadolinium administration  (<a class="graphic graphic_table graphicRef109029" href="/z/d/graphic/109029.html" rel="external">table 2</a> and <a class="graphic graphic_diagnosticimage graphicRef59777" href="/z/d/graphic/59777.html" rel="external">image 1</a>). (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of meningioma includes a wide range of neoplastic and non-neoplastic entities  (<a class="graphic graphic_table graphicRef109028" href="/z/d/graphic/109028.html" rel="external">table 3</a>). However, these are rare and almost always diagnosed after tissue is obtained, due to their clinical and radiographic similarity to meningiomas. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A definitive diagnosis of meningioma and classification as benign, atypical, or malignant requires histologic confirmation at the time of biopsy or surgery. For small and minimally symptomatic tumors, the diagnosis is based on characteristic imaging findings. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H108402839"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Black, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010; 99:307.</a></li><li class="breakAll">Central Brain Tumor Registry of the United States. Reports and tables 2010. http://www.cbtrus.org/reports/reports.html (Accessed on October 12, 2010).</li><li><a class="nounderline abstract_t">Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl 4:iv1.</a></li><li><a class="nounderline abstract_t">Liu Y, Li F, Zhu S, et al. Clinical features and treatment of meningiomas in children: report of 12 cases and literature review. Pediatr Neurosurg 2008; 44:112.</a></li><li><a class="nounderline abstract_t">Marosi C, Hassler M, Roessler K, et al. Meningioma. Crit Rev Oncol Hematol 2008; 67:153.</a></li><li><a class="nounderline abstract_t">Banerjee J, Pääkkö E, Harila M, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009; 11:543.</a></li><li><a class="nounderline abstract_t">Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57:1088.</a></li><li><a class="nounderline abstract_t">Cao J, Yan W, Li G, et al. Incidence and survival of benign, borderline, and malignant meningioma patients in the United States from 2004 to 2018. Int J Cancer 2022; 151:1874.</a></li><li><a class="nounderline abstract_t">Willis J, Smith C, Ironside JW, et al. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 2005; 31:141.</a></li><li><a class="nounderline abstract_t">Pearson BE, Markert JM, Fisher WS, et al. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 2008; 24:E3.</a></li><li><a class="nounderline abstract_t">Umansky F, Shoshan Y, Rosenthal G, et al. Radiation-induced meningioma. Neurosurg Focus 2008; 24:E7.</a></li><li><a class="nounderline abstract_t">Braganza MZ, Kitahara CM, Berrington de González A, et al. Ionizing radiation and the risk of brain and central nervous system tumors: A systematic review. Neuro Oncol 2012; 14:1316.</a></li><li><a class="nounderline abstract_t">Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102:1083.</a></li><li><a class="nounderline abstract_t">Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:5287.</a></li><li><a class="nounderline abstract_t">Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2017; 35:1570.</a></li><li><a class="nounderline abstract_t">Kok JL, Teepen JC, van Leeuwen FE, et al. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol 2019; 21:392.</a></li><li><a class="nounderline abstract_t">Withrow DR, Anderson H, Armstrong GT, et al. Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer. JAMA Oncol 2022; 8:1756.</a></li><li><a class="nounderline abstract_t">Ron E, Modan B, Boice JD Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988; 319:1033.</a></li><li><a class="nounderline abstract_t">Preston-Martin S, Yu MC, Henderson BE, Roberts C. Risk factors for meningiomas in men in Los Angeles County. J Natl Cancer Inst 1983; 70:863.</a></li><li><a class="nounderline abstract_t">Preston-Martin S, Mack W, Henderson BE. Risk factors for gliomas and meningiomas in males in Los Angeles County. Cancer Res 1989; 49:6137.</a></li><li><a class="nounderline abstract_t">Ryan P, Lee MW, North B, McMichael AJ. Amalgam fillings, diagnostic dental x-rays and tumours of the brain and meninges. Eur J Cancer B Oral Oncol 1992; 28B:91.</a></li><li><a class="nounderline abstract_t">Longstreth WT Jr, Phillips LE, Drangsholt M, et al. Dental X-rays and the risk of intracranial meningioma: a population-based case-control study. Cancer 2004; 100:1026.</a></li><li><a class="nounderline abstract_t">Claus EB, Calvocoressi L, Bondy ML, et al. Dental x-rays and risk of meningioma. Cancer 2012; 118:4530.</a></li><li><a class="nounderline abstract_t">Lin MC, Lee CF, Lin CL, et al. Dental diagnostic X-ray exposure and risk of benign and malignant brain tumors. Ann Oncol 2013; 24:1675.</a></li><li><a class="nounderline abstract_t">Preston-Martin S, Paganini-Hill A, Henderson BE, et al. Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst 1980; 65:67.</a></li><li><a class="nounderline abstract_t">Calnon WR. Shortcomings of study on dental x-rays and risk of meningioma. Cancer 2013; 119:464.</a></li><li><a class="nounderline abstract_t">Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 380:499.</a></li><li><a class="nounderline abstract_t">Davis F, Il'yasova D, Rankin K, et al. Medical diagnostic radiation exposures and risk of gliomas. Radiat Res 2011; 175:790.</a></li><li><a class="nounderline abstract_t">Grant IS. Necrotising fasciitis. Lancet 1994; 344:1770.</a></li><li><a class="nounderline abstract_t">Plyusnin A, Vapalahti O, Vasilenko V, et al. Dobrava hantavirus in Estonia: does the virus exist throughout Europe? Lancet 1997; 349:1369.</a></li><li><a class="nounderline abstract_t">Preston DL, Ron E, Yonehara S, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst 2002; 94:1555.</a></li><li><a class="nounderline abstract_t">Asgharian B, Chen YJ, Patronas NJ, et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 2004; 10:869.</a></li><li><a class="nounderline abstract_t">Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010; 99:341.</a></li><li><a class="nounderline abstract_t">Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84:603.</a></li><li><a class="nounderline abstract_t">Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001; 60:994.</a></li><li><a class="nounderline abstract_t">Larson JJ, van Loveren HR, Balko MG, Tew JM Jr. Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas. J Neurosurg 1995; 83:596.</a></li><li><a class="nounderline abstract_t">Carroll RS, Zhang J, Dashner K, et al. Androgen receptor expression in meningiomas. J Neurosurg 1995; 82:453.</a></li><li><a class="nounderline abstract_t">Blankenstein MA, Verheijen FM, Jacobs JM, et al. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000; 65:795.</a></li><li><a class="nounderline abstract_t">Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42:109.</a></li><li><a class="nounderline abstract_t">Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg 2003; 99:848.</a></li><li><a class="nounderline abstract_t">Wigertz A, Lönn S, Mathiesen T, et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006; 164:629.</a></li><li><a class="nounderline abstract_t">Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008; 26:279.</a></li><li><a class="nounderline abstract_t">Benson VS, Pirie K, Green J, et al. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008; 99:185.</a></li><li><a class="nounderline abstract_t">Lee E, Grutsch J, Persky V, et al. Association of meningioma with reproductive factors. Int J Cancer 2006; 119:1152.</a></li><li><a class="nounderline abstract_t">Claus EB, Calvocoressi L, Bondy ML, et al. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013; 118:649.</a></li><li><a class="nounderline abstract_t">Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015; 136:2369.</a></li><li><a class="nounderline abstract_t">Muskens IS, Wu AH, Porcel J, et al. Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. Neuro Oncol 2019; 21:498.</a></li><li class="breakAll">Cyproterone-containing medicinal products: Restrictions in use of cyproterone due to meningioma risk. European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-containing-medicinal-products (Accessed on March 30, 2021).</li><li class="breakAll">Restrictions in use of cyproterone due to meningioma risk. EMA/14775/2020. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_en-0.pdf (Accessed on March 30, 2021).</li><li><a class="nounderline abstract_t">Champeaux-Depond C, Weller J, Froelich S, Sartor A. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol 2021; 151:331.</a></li><li><a class="nounderline abstract_t">Samoyeau T, Provost C, Roux A, et al. Meningioma in patients exposed to progestin drugs: results from a real-life screening program. J Neurooncol 2022; 160:127.</a></li><li><a class="nounderline abstract_t">Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer 2002; 94:1626.</a></li><li><a class="nounderline abstract_t">Degeneffe A, De Maertelaer V, De Witte O, Lefranc F. The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6:e2318620.</a></li><li><a class="nounderline abstract_t">Johnson DR, Olson JE, Vierkant RA, et al. Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study. Neuro Oncol 2011; 13:1011.</a></li><li><a class="nounderline abstract_t">Michaud DS, Bové G, Gallo V, et al. Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 2011; 4:1385.</a></li><li><a class="nounderline abstract_t">Wiedmann M, Brunborg C, Lindemann K, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer 2013; 109:289.</a></li><li><a class="nounderline abstract_t">Schildkraut JM, Calvocoressi L, Wang F, et al. Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg 2014; 120:820.</a></li><li><a class="nounderline abstract_t">Niedermaier T, Behrens G, Schmid D, et al. Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology 2015; 85:1342.</a></li><li><a class="nounderline abstract_t">Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016; 375:794.</a></li><li><a class="nounderline abstract_t">Preston-Martin S, Pogoda JM, Schlehofer B, et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 1998; 27:579.</a></li><li><a class="nounderline abstract_t">Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998; 9:109.</a></li><li><a class="nounderline abstract_t">Preston-Martin S, Henderson BE, Yu MC. Epidemiology of intracranial meningiomas: Los Angeles Country, California. Neuroepidemiology 1983; 2:164.</a></li><li><a class="nounderline abstract_t">Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016; 131:803.</a></li><li class="breakAll">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.</li><li><a class="nounderline abstract_t">Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231.</a></li><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li class="breakAll">Perry A, Louis DN, Scheithauer BW, et al. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon 2007. p.164.</li><li><a class="nounderline abstract_t">Yang SY, Park CK, Park SH, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008; 79:574.</a></li><li><a class="nounderline abstract_t">Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008; 71:1388.</a></li><li><a class="nounderline abstract_t">Palma L, Celli P, Franco C, et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997; 86:793.</a></li><li><a class="nounderline abstract_t">Perry A, Scheithauer BW, Stafford SL, et al. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85:2046.</a></li><li><a class="nounderline abstract_t">Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 2010; 99:433.</a></li><li><a class="nounderline abstract_t">Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg 2016; 124:106.</a></li><li><a class="nounderline abstract_t">Juratli TA, McCabe D, Nayyar N, et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol 2018; 136:779.</a></li><li><a class="nounderline abstract_t">Sahm F, Schrimpf D, Olar A, et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. J Natl Cancer Inst 2016; 108.</a></li><li><a class="nounderline abstract_t">Goutagny S, Nault JC, Mallet M, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014; 24:184.</a></li><li><a class="nounderline abstract_t">Juratli TA, Thiede C, Koerner MVA, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget 2017; 8:109228.</a></li><li><a class="nounderline abstract_t">Mirian C, Duun-Henriksen AK, Juratli T, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 2020; 91:378.</a></li><li><a class="nounderline abstract_t">Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 2020; 140:409.</a></li><li><a class="nounderline abstract_t">Behling F, Fodi C, Gepfner-Tuma I, et al. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol 2021; 23:1273.</a></li><li><a class="nounderline abstract_t">Nassiri F, Wang JZ, Singh O, et al. Loss of H3K27me3 in meningiomas. Neuro Oncol 2021; 23:1282.</a></li><li><a class="nounderline abstract_t">Katz LM, Hielscher T, Liechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 2018; 135:955.</a></li><li><a class="nounderline abstract_t">Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017; 18:682.</a></li><li><a class="nounderline abstract_t">Nassiri F, Mamatjan Y, Suppiah S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 2019; 21:901.</a></li><li><a class="nounderline abstract_t">Nassiri F, Liu J, Patil V, et al. A clinically applicable integrative molecular classification of meningiomas. Nature 2021; 597:119.</a></li><li><a class="nounderline abstract_t">Maas SLN, Stichel D, Hielscher T, et al. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. J Clin Oncol 2021; 39:3839.</a></li><li><a class="nounderline abstract_t">Driver J, Hoffman SE, Tavakol S, et al. A molecularly integrated grade for meningioma. Neuro Oncol 2022; 24:796.</a></li><li><a class="nounderline abstract_t">Choy W, Kim W, Nagasawa D, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 2011; 30:E6.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285.</a></li><li><a class="nounderline abstract_t">Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339:1077.</a></li><li><a class="nounderline abstract_t">Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 2016; 18:649.</a></li><li><a class="nounderline abstract_t">Strickland MR, Gill CM, Nayyar N, et al. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg 2017; 127:438.</a></li><li><a class="nounderline abstract_t">Peyre M, Gaillard S, de Marcellus C, et al. Progestin-associated shift of meningioma mutational landscape. Ann Oncol 2018; 29:681.</a></li><li><a class="nounderline abstract_t">Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 2013; 19:1180.</a></li><li><a class="nounderline abstract_t">Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004; 363:1535.</a></li><li><a class="nounderline abstract_t">Mattox A, Hughes B, Oleson J, et al. Treatment recommendations for primary extradural meningiomas. Cancer 2011; 117:24.</a></li><li><a class="nounderline abstract_t">Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821.</a></li><li><a class="nounderline abstract_t">Annegers JF, Schoenberg BS, Okazaki H, Kurland LT. Epidemiologic study of primary intracranial neoplasms. Arch Neurol 1981; 38:217.</a></li><li><a class="nounderline abstract_t">Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol 1987; 27:319.</a></li><li><a class="nounderline abstract_t">Islim AI, Mohan M, Moon RDC, et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol 2019; 142:211.</a></li><li><a class="nounderline abstract_t">Cleary JO, Yeung J, McMeekin H, et al. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Nucl Med Commun 2016; 37:1197.</a></li><li><a class="nounderline abstract_t">Niiro M, Yatsushiro K, Nakamura K, et al. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry 2000; 68:25.</a></li><li><a class="nounderline abstract_t">Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998; 51:1718.</a></li><li><a class="nounderline abstract_t">Morris Z, Whiteley WN, Longstreth WT Jr, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2009; 339:b3016.</a></li><li><a class="nounderline abstract_t">Bos D, Poels MM, Adams HH, et al. Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-based Rotterdam Scan Study. Radiology 2016; 281:507.</a></li><li><a class="nounderline abstract_t">Cerhan JH, Butts AM, Syrjanen JA, et al. Factors Associated With Meningioma Detected in a Population-Based Sample. Mayo Clin Proc 2019; 94:254.</a></li><li><a class="nounderline abstract_t">Englot DJ, Magill ST, Han SJ, et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg 2016; 124:1552.</a></li><li><a class="nounderline abstract_t">Pieper DR, Al-Mefty O, Hanada Y, Buechner D. Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion. Neurosurgery 1999; 44:742.</a></li><li><a class="nounderline abstract_t">Hsu CC, Pai CY, Kao HW, et al. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci 2010; 17:584.</a></li><li><a class="nounderline abstract_t">Zhang H, Rödiger LA, Shen T, et al. Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology 2008; 50:525.</a></li><li><a class="nounderline abstract_t">Nagar VA, Ye JR, Ng WH, et al. Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol 2008; 29:1147.</a></li><li><a class="nounderline abstract_t">Hwang WL, Marciscano AE, Niemierko A, et al. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol 2016; 18:863.</a></li><li><a class="nounderline abstract_t">Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010; 99:393.</a></li><li><a class="nounderline abstract_t">Nowosielski M, Galldiks N, Iglseder S, et al. Diagnostic challenges in meningioma. Neuro Oncol 2017; 19:1588.</a></li><li><a class="nounderline abstract_t">Galldiks N, Albert NL, Sommerauer M, et al. PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol 2017; 19:1576.</a></li><li><a class="nounderline abstract_t">Johnson MD, Powell SZ, Boyer PJ, et al. Dural lesions mimicking meningiomas. Hum Pathol 2002; 33:1211.</a></li><li><a class="nounderline abstract_t">Tu PH, Giannini C, Judkins AR, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: A primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23:5718.</a></li><li><a class="nounderline abstract_t">Tan LA, Kasliwal MK, Wewel J, et al. Neurosarcoidosis mimicking bilateral posterior fossa tentorial meningiomas. J Neurooncol 2015; 125:435.</a></li><li><a class="nounderline abstract_t">Kahraman-Koytak P, Bruce BB, Peragallo JH, et al. Diagnostic Errors in Initial Misdiagnosis of Optic Nerve Sheath Meningiomas. JAMA Neurol 2019; 76:326.</a></li></ol></div><div id="topicVersionRevision">Topic 5220 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20821343" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and etiology of meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20821343" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology and etiology of meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230924" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical features and treatment of meningiomas in children: report of 12 cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342535" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179425" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radiation-induced meningiomas: a shadow in the success story of childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16331155" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of intracranial meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35779059" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence and survival of benign, borderline, and malignant meningioma patients in the United States from 2004 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15771707" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The accuracy of meningioma grading: a 10-year retrospective audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18447742" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18447746" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Radiation-induced meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22952197" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634481" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079138" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339329" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099534" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36201196" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3173432" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tumors of the brain and nervous system after radiotherapy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6573530" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors for meningiomas in men in Los Angeles County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2790826" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors for gliomas and meningiomas in males in Los Angeles County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1306734" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Amalgam fillings, diagnostic dental x-rays and tumours of the brain and meninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14983499" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dental X-rays and the risk of intracranial meningioma: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492363" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dental x-rays and risk of meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406732" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dental diagnostic X-ray exposure and risk of benign and malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6930521" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Case-control study of intracranial meningiomas in women in Los Angeles County, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254924" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Shortcomings of study on dental x-rays and risk of meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22681860" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21466382" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Medical diagnostic radiation exposures and risk of gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7997021" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Necrotising fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149707" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dobrava hantavirus in Estonia: does the virus exist throughout Europe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381708" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871962" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Meningiomas may be a component tumor of multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20714782" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Meningiomas and neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1484939" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A clinical study of type 2 neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589430" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545742" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7861224" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Androgen receptor expression in meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11108890" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Occurrence, regulation, and significance of progesterone receptors in human meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421067" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Expression of estrogen receptors alpha and beta in human meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609164" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sex steroid hormone exposures and risk for meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835295" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk of brain tumors associated with exposure to exogenous female sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182668" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Is there an association between meningioma and hormone replacement therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18560401" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570277" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of meningioma with reproductive factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23101448" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25335165" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30615143" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30615143" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30615143" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33394263" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cyproterone acetate and meningioma: a nationwide-wide population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36066786" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Meningioma in patients exposed to progestin drugs: results from a real-life screening program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920521" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The association between breast carcinoma and meningioma in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326990" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750006" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685234" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23778522" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24484233" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Endogenous and exogenous hormone exposure and the risk of meningioma in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26377253" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557308" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Body Fatness and Cancer--Viewpoint of the IARC Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758110" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An international case-control study of adult glioma and meningioma: the role of head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486470" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence of intracranial tumors following hospitalization for head injuries (Denmark).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epidemiology of intracranial meningiomas: Los Angeles Country, California</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157931" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157931" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766430" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294779" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126894" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10223247" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730473" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A review of malignant meningiomas: diagnosis, characteristics, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26274991" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30123936" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668184" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : TERT Promoter Mutations and Risk of Recurrence in Meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24261697" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29312603" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32041819" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32642869" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33367841" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33970242" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Loss of H3K27me3 in meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29627952" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314689" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31158293" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34433969" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A clinically applicable integrative molecular classification of meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34618539" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508644" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A molecularly integrated grade for meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21529177" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334667" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348505" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826201" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27885953" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29206892" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Progestin-associated shift of meningioma mutational landscape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406776" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : mTORC1 inhibitors suppress meningioma growth in mouse models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135603" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824719" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Treatment recommendations for primary extradural meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978290" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incidental findings on brain MRI in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7213145" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Epidemiologic study of primary intracranial neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3824137" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Incidental meningiomas in autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656531" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27399848" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601396" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Natural history of elderly patients with asymptomatic meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855530" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The natural history of asymptomatic meningiomas in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687093" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27337027" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-based Rotterdam Scan Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711123" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Factors Associated With Meningioma Detected in a Population-Based Sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26636386" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Seizures in supratentorial meningioma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201298" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219376" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379768" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Perfusion MR imaging for differentiation of benign and malignant meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356472" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597949" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20740303" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intracranial meningiomas of atypical (WHO grade II) histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28531331" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Diagnostic challenges in meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605532" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : PET imaging in patients with meningioma-report of the RANO/PET Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514791" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Dural lesions mimicking meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009945" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341372" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Neurosarcoidosis mimicking bilateral posterior fossa tentorial meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30556835" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Diagnostic Errors in Initial Misdiagnosis of Optic Nerve Sheath Meningiomas.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
